Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older, of any gender
- People who have been diagnosed with stage IV cancer (such as lung, colorectal, breast, liver, or stomach cancer) and whose doctor has recommended treatment with immune checkpoint inhibitor (immunotherapy) drugs, either as a first or second treatment option — chemotherapy given alongside immunotherapy is permitted
- A tissue or cell sample (taken by biopsy or fine needle) is available for testing
- People who are able and willing to follow the treatment plan as required by the trial
- People who have given their consent to take part in the study
Who may not be able to join:
- People who have already begun immunotherapy (immune checkpoint inhibitor) treatment before enrolling in the trial
- People whose immunotherapy is being used as a consolidation treatment (for example, Durvalumab used after another treatment)
- People who have already started chemotherapy before enrolling in the trial
- People who have health conditions, mental health conditions, or work responsibilities that may make it difficult to follow the trial's treatment plan
- People who have not agreed to participate in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sinh D Nguyen, MGI
Phone: +84888843489
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To investigate the relationship between ctDNA dynamics and clinical response to immune checkpoint inhibitors (ICIs) (assessed by RECIST 1.1).; To compare and combine ctDNA dynamics and RECIST1.1 to predict clinical response in case of pseudoprogression; To investigate the prognostic value of ctDNA clearance with PFS and OS; To compare the prognostic values of PD-L1, TMB and MSI in predicting clinical response to ICI, best indicator(s) for ICI response.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.